AR052162A1 - Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol - Google Patents
Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazolInfo
- Publication number
- AR052162A1 AR052162A1 ARP050105257A ARP050105257A AR052162A1 AR 052162 A1 AR052162 A1 AR 052162A1 AR P050105257 A ARP050105257 A AR P050105257A AR P050105257 A ARP050105257 A AR P050105257A AR 052162 A1 AR052162 A1 AR 052162A1
- Authority
- AR
- Argentina
- Prior art keywords
- amphotericin
- formulation
- particles
- particle size
- posaconazole
- Prior art date
Links
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 title abstract 3
- 229960001589 posaconazole Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 229960004413 flucytosine Drugs 0.000 abstract 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940102213 injectable suspension Drugs 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229960002722 terbinafine Drugs 0.000 abstract 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones utiles para el tratamiento de infecciones, en particular, formulaciones que incluyen el ingrediente farmacéutico activo Posaconozal en una suspension inyectable de partículas que es estable cuando se la somete a la esterilizacion por vapor terminal. Se observo que los tamanos medios de partículas que se prefieren y que oscilan entre 1,5 y 3,0 micrones dan como resultado características farmacocinéticas superiores, tales como las que se presentan a continuacion. Reivindicacion 1: Una formulacion que comprende una suspension de posaconazol estabilizada por un fosfolípido, en una mezcla que comprende agua, un termoprotector y un sistema de amortiguador, donde dicho Posaconazol tiene una distribucion de tamano de partícula con un valor medio de tamano de partícula que oscila ente 1,5 y 3,0 micrones aproximadamente. Reivindicacion 18: La formulacion de la reivindicacion 1, que comprende además un segundo ingrediente activo que se selecciona entre uno o más del grupo que consiste en antifungicos, anfotericina B, deoxicolato de anfotericina B; flucitosina, terbinafina, antibacterianos, antivirales, esteroides, fármacos antiinflamatorios no esteroides (ôNSAIDö), fármacos quimioterapéuticos y antieméticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/140,294 US20060009469A1 (en) | 2004-05-28 | 2005-05-27 | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052162A1 true AR052162A1 (es) | 2007-03-07 |
Family
ID=36354136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105257A AR052162A1 (es) | 2005-05-27 | 2005-12-15 | Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060009469A1 (es) |
| AR (1) | AR052162A1 (es) |
| PE (1) | PE20061154A1 (es) |
| TW (1) | TW200640459A (es) |
| WO (1) | WO2006130177A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343053A1 (en) * | 2006-05-30 | 2011-07-13 | Elan Pharma International Limited | Nanoparticulate posaconazole formulations |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| EP2130540A1 (en) | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
| WO2009157009A1 (en) * | 2008-06-25 | 2009-12-30 | Akums Drugs And Pharmaceuticals Limited | An intravenous drug delivery system |
| WO2011124572A1 (en) * | 2010-04-09 | 2011-10-13 | Unilever Plc | Oral care compositions |
| EP3391890B1 (en) * | 2010-06-29 | 2021-08-25 | Merck Sharp & Dohme Corp. | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| JP5341059B2 (ja) | 2010-11-09 | 2013-11-13 | 株式会社大塚製薬工場 | 幹細胞懸濁液 |
| US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| KR20160033795A (ko) | 2012-02-28 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| CN103664622B (zh) * | 2012-09-18 | 2016-01-13 | 浙江工业大学 | Ab型羟基改性高聚物的单体及其中间体和制备方法 |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3544983A1 (de) * | 1985-12-19 | 1987-06-25 | Hoechst Ag | Antimykotisch wirksamer nagellack |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| US5703079A (en) * | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| US6461622B2 (en) * | 1994-09-07 | 2002-10-08 | Johnson & Johnson Consumer Companies, Inc. | Topical compositions |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| KR100635456B1 (ko) * | 1998-05-29 | 2006-10-18 | 스키에파마 캐나다 인코포레이티드 | 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법 |
| EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| KR100784752B1 (ko) * | 2000-02-04 | 2007-12-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 안정한 에멀젼 조성물 |
| TWI354568B (en) * | 2000-09-20 | 2011-12-21 | Jagotec Ag | Insoluble drug particle compositions with improved |
| US20020193369A1 (en) * | 2000-11-02 | 2002-12-19 | Markham Penelope N. | Antifungal compounds and uses therefor |
| US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| EP2090165A3 (en) * | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| CA2499897A1 (en) * | 2002-09-23 | 2004-04-01 | Schering Corporation | Use of posaconazole for the treatment of fungal infections |
| JP2007513937A (ja) * | 2003-12-09 | 2007-05-31 | ファイザー インコーポレイテッド | Ｈｉｖプロテアーゼ阻害剤を含む組成物 |
| PE20060291A1 (es) * | 2004-05-28 | 2006-04-14 | Schering Corp | Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas |
-
2005
- 2005-05-27 US US11/140,294 patent/US20060009469A1/en not_active Abandoned
- 2005-12-14 PE PE2005001463A patent/PE20061154A1/es not_active Application Discontinuation
- 2005-12-14 WO PCT/US2005/045297 patent/WO2006130177A1/en not_active Ceased
- 2005-12-14 TW TW094144302A patent/TW200640459A/zh unknown
- 2005-12-15 AR ARP050105257A patent/AR052162A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006130177A1 (en) | 2006-12-07 |
| US20060009469A1 (en) | 2006-01-12 |
| PE20061154A1 (es) | 2006-11-09 |
| TW200640459A (en) | 2006-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052162A1 (es) | Composiciones farmaceuticas inyectables estabilizadas con particulados de posaconazol | |
| DOP2012000064A (es) | Formulaciones farmaceuticas muy concentradas | |
| MX2009012964A (es) | Formulacion de peptido estable a alta temperatura. | |
| PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
| CU24504B1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol y un proceso que incluye un paso de granulación para preparar el mismo | |
| CO7111300A2 (es) | Formulación de anticuerpos | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| ES2591352T3 (es) | Composición de tacrolimus estabilizada | |
| PE20241346A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
| BRPI0607549A2 (pt) | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos | |
| PE20060291A1 (es) | Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas | |
| CU23318A7 (es) | Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida | |
| AR068820A1 (es) | Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso | |
| MX375427B (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| Kaur et al. | Inhalational drug delivery in pulmonary aspergillosis | |
| MX2015011624A (es) | Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras. | |
| MX384159B (es) | Formulaciones y métodos para el suministro vaginal de antiprogestinas. | |
| AR052882A1 (es) | Composicion antihelmintica | |
| US20060269578A1 (en) | Microemulsions and its use for preventing airway diseases | |
| AR086448A1 (es) | Composicion farmaceutica que comprende drotaverina | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |